Enhertu backed for HER2+ tumours
EU panel recommends Enhertu for HER2-positive solid tumors, a key milestone for the treatment. This may impact Daiichi Sankyo and AstraZeneca
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.